Combination Therapy of Gemcitabine and Irinotecan in Advanced Biliary Tract Cancer: Phase II Trial

被引：0
|
作者：
Chung, Moon Jae
Park, Semi
Park, Jeong Youp
Bang, Seungmin
Park, Seung Woo
Song, Si Young
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
W1896
引用
收藏
页码：S761 / S761
页数：1
相关论文
共 50 条
  • [31] Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
    Takashi Sasaki
    Hiroyuki Isayama
    Yousuke Nakai
    Yukiko Ito
    Hirofumi Kogure
    Osamu Togawa
    Nobuo Toda
    Ichiro Yasuda
    Osamu Hasebe
    Iruru Maetani
    Naoki Sasahira
    Kenji Hirano
    Takeshi Tsujino
    Minoru Tada
    Masao Omata
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 1101 - 1107
  • [32] Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial
    Markussen, Alice
    Jensen, Lars Henrik
    Diness, Laura Vittrup
    Larsen, Finn Ole
    CANCERS, 2020, 12 (07) : 1 - 10
  • [33] Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Ito, Yukiko
    Kogure, Hirofumi
    Togawa, Osamu
    Toda, Nobuo
    Yasuda, Ichiro
    Hasebe, Osamu
    Maetani, Iruru
    Sasahira, Naoki
    Hirano, Kenji
    Tsujino, Takeshi
    Tada, Minoru
    Omata, Masao
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1101 - 1107
  • [34] Phase II trial of weekly Docetaxel/Irinotecan combination in advanced pancreatic cancer
    Burtness, Barbara
    Thomas, Laurie
    Sipples, Rebecca
    McGurk, Meghan
    Salikooti, Saritha
    Christoforou, Maryanne
    Mirto, Gayle
    Salem, Ronald
    Sosa, Julieann
    Kloss, Robert
    Rahman, Zia
    Chung, Gina
    Lacy, Jill
    Murren, John R.
    CANCER JOURNAL, 2007, 13 (04): : 257 - 262
  • [35] Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer
    Burtness, B.
    Gibson, M.
    Egleston, B.
    Mehra, R.
    Thomas, L.
    Sipples, R.
    Quintanilla, M.
    Lacy, J.
    Watkins, S.
    Murren, J. R.
    Forastiere, A. A.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1242 - 1248
  • [36] Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study
    Larsen, Finn Ole
    Markussen, Alice
    Diness, Laura V.
    Nielsen, Dorte
    ONCOLOGY, 2018, 94 (01) : 19 - 24
  • [37] Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer.
    Burtness, B
    Sipples, R
    Mirto, G
    Thomas, L
    Ahman, ZA
    Kloss, RA
    Murren, J
    Lacy, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 342S - 342S
  • [38] A phase I trial of fixed-dose-rate (FDR) gemcitabine and irinotecan combination in patients with advanced pancreatic and biliary cancer.
    Sun, W
    Theobald, ME
    Hershock, D
    Haller, DG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 341S - 341S
  • [39] Gemcitabine plus oxaliplatin combination in patients with advanced biliary tract cancer
    Vattemi, E.
    Lusso, M.
    Pedersini, R.
    Baier, S.
    Cretella, E.
    Petric, M.
    Stocker, J.
    Graiff, C.
    ANNALS OF ONCOLOGY, 2007, 18 : VII111 - VII111
  • [40] A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
    Laura W. Goff
    Dana B. Cardin
    Jennifer G. Whisenant
    Liping Du
    Tatsuki Koyama
    Kimberly B. Dahlman
    Safia N. Salaria
    Ruth T. Young
    Kristen K. Ciombor
    Jill Gilbert
    Stephen James Smith
    Emily Chan
    Jordan Berlin
    Investigational New Drugs, 2017, 35 : 95 - 104
12345